Comparison of gefitinib and erlotinib efficacies as third-line therapy for advanced non-small-cell lung cancer

Author

SHAO, Yu-Yun^{1 3} ; SHAU, Wen-Yi⁶ ; LIN, Zhong-Zhe^{1 5 7} ; CHEN, Ho-Min² ; KUO, Raymond² ; YANG, James Chih-Hsin^{1 3 4} ; LAI, Mei-Shu^{2 8 9}
[1] Department of Oncology, National Taiwan University Hospital, 7, Chung-Shan S Rd., Taipei 10002, Taiwan, Province of China
[2] Center for Comparative Effectiveness Research, National Center of Excellence for Clinical Trial and Research, National Taiwan University Hospital, 7, Chung-Shan S Rd., Taipei 10002, Taiwan, Province of China
[3] Graduate Institute of Oncology, College of Medicine, National Taiwan University, 1, Sec. 1, Ren'ai Rd., Taipei City 10051, Taiwan, Province of China
[4] Cancer Research Center, College of Medicine, National Taiwan University, 1, Sec. 1, Ren'ai Rd., Taipei City 10051, Taiwan, Province of China
[5] Department of Internal Medicine, College of Medicine, National Taiwan University, 1, Sec. 1, Ren'ai Rd., Taipei City 10051, Taiwan, Province of China
[6] Division of Health Technology Assessment, Center For Drug Evaluation, 3F, No. 465, Sec. 6, Zhongxiao E. Rd., Taipei 11557, Taiwan, Province of China
[7] Department of Oncology, National Taiwan University Hospital, Yun-Lin Branch, 95, Xuefu Rd., Huwei Township, Yunlin County 63252, Yunlin, Taiwan, Province of China
[8] Taiwan Cancer Registry, P. O. Box 84-310 Taipei, Taipei City 10099, Taiwan, Province of China
[9] Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, No. 17, Xuzhou Rd., Taipei 10055, Taiwan, Province of China

Source

European journal of cancer (1990). 2013, Vol 49, Num 1, pp 106-114, 9 p ; ref : 32 ref

ISSN

0959-8049

Scientific domain

Medical oncology; Pharmacology drugs

Publisher

Elsevier, Kidlington

Publication country

United Kingdom

Document type

Article

Language

English

Author keyword

Comparative effectiveness Erlotinib Gefitinib Non-small-cell lung cancer Prognosis

Keyword (fr)

Anticancéreux Cancer du poumon Cancérologie Carcinome non petite cellule bronchopulmonaire Efficacité traitement Erlotinib Etude comparative Géfitinib Pronostic Stade avancé Anti-EGFR Inhibiteur de la tyrosine kinase de l'EGFR Traitement de troisième intention Cancer Dérivé de la quinazoline Enzyme Inhibiteur de la tyrosine kinase Inhibiteur enzyme Pathologie de l'appareil respiratoire Pathologie des bronches Pathologie des poumons Protein-tyrosine kinase Transferases Tumeur maligne

Keyword (en)

Antineoplastic agent Lung cancer Cancerology non-small cell lung carcinoma Treatment efficiency Erlotinib Comparative study Gefitinib Prognosis Advanced stage Third line treatment Cancer Quinazoline derivatives Enzyme Tyrosine kinase inhibitor Enzyme inhibitor Respiratory disease Bronchus disease Lung disease Protein-tyrosine kinase Transferases Malignant tumor

Keyword (es)

Anticanceroso Cáncer del pulmón Cancerología Carcinoma no pequeňa célula bronchopulmonar Eficacia tratamiento Erlotinib Estudio comparativo Gefitinib Pronóstico Estadio avanzado Cáncer Enzima Inhibidor tyrosine kinase Inhibidor enzima Aparato respiratorio patología Bronquio patología Pulmón patología Protein-tyrosine kinase Transferases Tumor maligno

Classification

Pascal

002 Biological and medical sciences / 002B Medical sciences / 002B02 Pharmacology. Drug treatments

Pascal

002 Biological and medical sciences / 002B Medical sciences / 002B04 Tumors

Discipline

General pharmacology Tumours

Origin

Inist-CNRS

Database

PASCAL

INIST identifier

26821425

Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS